Search Results - kylie+walters

2 Results

Sort By:

Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for three small molecules that target hRpn13, an overexpressed protein in certain cancers. Description of Technology: Over 35,000 new cases of multiple myeloma are diagnosed each year in the US. Standard of care and experimental therapies include...

Published: 12/20/2024 | Inventor(s): Kylie Walters, Xiuxiu Lu

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Licensing

A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer

This technology includes a new chemical scaffold (with lead compound XL5) against hRpn13 that induces apoptosis, which may have clinical efficacy against cancer. The structure of XL5-conjugated hRpn13 guided the design of XL5-PROTAC degrader compounds that exhibit greater efficacy than previous hRpn13-targeting compounds, as evaluated by selectivity...

Published: 8/12/2024 | Inventor(s): Venkatareddy Sabbasani, Kylie Walters, Xiuxiu Lu, Nadya Tarasova, Rolf Swenson

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology